JP2017530195A5 - - Google Patents

Download PDF

Info

Publication number
JP2017530195A5
JP2017530195A5 JP2017536991A JP2017536991A JP2017530195A5 JP 2017530195 A5 JP2017530195 A5 JP 2017530195A5 JP 2017536991 A JP2017536991 A JP 2017536991A JP 2017536991 A JP2017536991 A JP 2017536991A JP 2017530195 A5 JP2017530195 A5 JP 2017530195A5
Authority
JP
Japan
Prior art keywords
rivastigmine
formulation
aqueous
nasal
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017536991A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017530195A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2015/050591 external-priority patent/WO2016049700A1/en
Publication of JP2017530195A publication Critical patent/JP2017530195A/ja
Publication of JP2017530195A5 publication Critical patent/JP2017530195A5/ja
Priority to JP2020036966A priority Critical patent/JP7357571B2/ja
Pending legal-status Critical Current

Links

JP2017536991A 2014-10-03 2015-09-30 神経学的及び神経変性疾患及び障害を処置するための鼻腔投与組成物 Pending JP2017530195A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2020036966A JP7357571B2 (ja) 2014-10-03 2020-03-04 神経学的及び神経変性疾患及び障害を処置するための鼻腔投与組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2014903944A AU2014903944A0 (en) 2014-10-03 Intranasal compositions for treatment of neurological and neurodegenerative diseases and disorders
AU2014903944 2014-10-03
PCT/AU2015/050591 WO2016049700A1 (en) 2014-10-03 2015-09-30 Intranasal compositions for treatment of neurological and neurodegenerative diseases and disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020036966A Division JP7357571B2 (ja) 2014-10-03 2020-03-04 神経学的及び神経変性疾患及び障害を処置するための鼻腔投与組成物

Publications (2)

Publication Number Publication Date
JP2017530195A JP2017530195A (ja) 2017-10-12
JP2017530195A5 true JP2017530195A5 (enExample) 2018-11-08

Family

ID=55629161

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017536991A Pending JP2017530195A (ja) 2014-10-03 2015-09-30 神経学的及び神経変性疾患及び障害を処置するための鼻腔投与組成物
JP2020036966A Active JP7357571B2 (ja) 2014-10-03 2020-03-04 神経学的及び神経変性疾患及び障害を処置するための鼻腔投与組成物
JP2021171712A Pending JP2022003100A (ja) 2014-10-03 2021-10-20 神経学的及び神経変性疾患及び障害を処置するための鼻腔投与組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020036966A Active JP7357571B2 (ja) 2014-10-03 2020-03-04 神経学的及び神経変性疾患及び障害を処置するための鼻腔投与組成物
JP2021171712A Pending JP2022003100A (ja) 2014-10-03 2021-10-20 神経学的及び神経変性疾患及び障害を処置するための鼻腔投与組成物

Country Status (12)

Country Link
US (3) US10471040B2 (enExample)
EP (1) EP3200828B1 (enExample)
JP (3) JP2017530195A (enExample)
AU (1) AU2015327762C1 (enExample)
CA (1) CA2961936C (enExample)
DK (1) DK3200828T3 (enExample)
ES (1) ES2822562T3 (enExample)
HU (1) HUE052441T2 (enExample)
PL (1) PL3200828T3 (enExample)
PT (1) PT3200828T (enExample)
SM (1) SMT202000576T1 (enExample)
WO (1) WO2016049700A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016049700A1 (en) * 2014-10-03 2016-04-07 Lachesis Biosciences Pty Ltd Intranasal compositions for treatment of neurological and neurodegenerative diseases and disorders
DK3698791T3 (da) * 2017-02-02 2024-01-15 Otolanum Ag Intranasal sammensætning, der omfatter betahistin
WO2022072318A1 (en) * 2020-10-01 2022-04-07 Lyra Therapeutics, Inc. Osmotic drug delivery implants
CA3180600A1 (en) * 2020-06-25 2021-12-30 Lachesis Biosciences Limited Methods of treating or preventing organophosphorus poisoning
US20230270672A1 (en) * 2020-08-07 2023-08-31 Council For Scientific And Industrial Research Microemulsion drug delivery system for treatment of acute respiratory distress syndrome
CN115919767B (zh) * 2022-10-13 2023-08-11 暨南大学 卡巴拉汀鼻喷雾剂及其制备方法
CN119523898A (zh) * 2024-12-02 2025-02-28 肇庆学院 多靶点药物的经鼻给药制剂及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR5733M (enExample) 1966-09-27 1968-01-22
US4806543A (en) 1986-11-25 1989-02-21 Board Of Trustees Of The Leland Stanford Junior University Method and compositions for reducing neurotoxic injury
FR2722989B1 (fr) 1994-07-29 1997-05-30 Synthelabo Utilisation de l'ifenprodil et de ses enantiomeres pour la preparation de medicaments utiles dans le traitement des neuropathies peripheriques et des maladies neurodegeneratives centrales
US6558560B2 (en) * 2001-07-27 2003-05-06 Hewlett-Packard Company Method for the fabrication of electrical contacts
WO2004034963A2 (en) * 2002-05-17 2004-04-29 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
US20030225031A1 (en) * 2002-05-21 2003-12-04 Quay Steven C. Administration of acetylcholinesterase inhibitors to the cerebral spinal fluid
US20040254146A1 (en) * 2002-05-21 2004-12-16 Nastech Pharmaceutical Company Inc. Carboxylate salts of galantamine and their pharmaceutical use
US20070292523A1 (en) * 2004-09-27 2007-12-20 Joey Moodley Dihydropyrimidine Formulations
US8058291B2 (en) * 2005-04-06 2011-11-15 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of CNS-related conditions
US8187570B1 (en) * 2005-01-04 2012-05-29 Gp Medical, Inc. Nanoparticles for protein drug delivery
US8911751B2 (en) * 2005-10-11 2014-12-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions for nasal delivery
ATE544444T1 (de) * 2005-10-11 2012-02-15 Yissum Res Dev Co Zusammensetzungen für die nasale abgabe
WO2007092329A2 (en) * 2006-02-03 2007-08-16 Avanir Pharmaceuticals Pharmaceutical compositions for treating depression, anxiety and neurodegenerative disorders
JP2009526063A (ja) * 2006-02-09 2009-07-16 シェーリング コーポレイション 医薬製剤
CN101784287B (zh) * 2007-06-26 2013-04-24 若素制药株式会社 水性组合物
FR2931677B1 (fr) * 2008-06-02 2010-08-20 Sanofi Aventis Association d'un agoniste partiel des recepteurs nicotiniques et d'un inhibiteur d'acetylcholinesterase, composition la contenant et son utilisation dans le traitement des troubles cognitifs
TWI519532B (zh) 2010-05-17 2016-02-01 艾維沃製藥公司 （Ｒ）－７－氯－Ｎ－（啶－３－基）苯並［b］噻吩－２－羧醯胺鹽酸鹽單水合物之結晶形體
US8673338B2 (en) * 2011-07-29 2014-03-18 Massachusetts Eye And Ear Infirmary Methods of delivering pharmaceutical agents
WO2016049700A1 (en) * 2014-10-03 2016-04-07 Lachesis Biosciences Pty Ltd Intranasal compositions for treatment of neurological and neurodegenerative diseases and disorders

Similar Documents

Publication Publication Date Title
JP6657454B2 (ja) ブプレノルフィンの乱用抵抗性粘膜付着性送達デバイス
KR102489453B1 (ko) 비강내 제약 분말 조성물
US20210308040A1 (en) Ketamine oral transmucosal delivery system
JP2012522783A5 (enExample)
HRP20150644T1 (hr) Metoda za lijeäśenje atrijalne fibrilacije
JP2018517676A5 (enExample)
JP2016512833A (ja) ウイルス感染症の治療薬としてのベラプロスト異性体
TW201016209A (en) Intranasal compositions, dosage forms and methods of treatments
JP2016525548A5 (enExample)
WO2013081565A1 (en) Pharmaceutical compositions comprising roflumilast and terbutaline
JP5775970B2 (ja) 口腔貼付剤
JP2008518007A5 (enExample)
JP2023545372A (ja) デクスメデトミジン塩酸塩を用いた双極性障害及び精神病の治療
RU2007119721A (ru) Частицы для лечения легочной инфекции
CN1735434A (zh) 用于预防和治疗伤风与类流感症状的包含精选粘附聚合物的组合物
JP2016502991A5 (enExample)
JP2013253038A (ja) 口腔内溶解型フィルム製剤
JPWO2010023874A1 (ja) ロペラミド塩酸塩含有フィルム製剤
KR20190009294A (ko) 비강 울혈을 치료/예방하기 위한 카르복실산
CN108024952A (zh) 在治疗发作中用于口颊施用以获得快速起效的咪达唑仑组合物
CN114585364B (zh) 谷氨酸2b受体拮抗剂和σ受体激动剂作为止咳药的用途
JP2015515971A5 (enExample)
CN105106250B (zh) 一种灵芝总三萜组合物及其制备方法
JP2014525891A5 (enExample)
CN118103072A (zh) 利用抗胆碱能剂治疗神经系统病症的方法